Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5047MR)

This product GTTS-WQ5047MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Heloderma suspectum
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5047MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14833MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ6620MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ13204MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ9202MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ15440MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ8061MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ3318MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ14966MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1314
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW